---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117678"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:12:44.070407+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Brainstorm reports Q3 net loss $1.2M; withdraws NurOwn BLA for ALS, cuts 30% headcount

## Summary
- Withdrew BLA for NurOwn in ALS after FDA advisory committee vote; FDA invites expedited meeting for path forward.
- Strategic realignment reduces headcount ~30%, targets cutting total resource consumption by half.
- Cash, equivalents, and short-term deposits at $1.4M as of Sep 30, 2023, down from $3M at Dec 31, 2022.
- Net loss for Q3 2023 was $1.2M ($0.03 per share) vs. $6.9M ($0.19 per share) in Q3 2022.
- Raised ~$7.5M gross in July 2023 registered direct offering with a single institutional investor.

## SEC filing metadata
- accession: 0001104659-23-117678
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/0001104659-23-117678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/tm2330690d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117678
- JSON: https://secwatch.observer/filing/0001104659-23-117678.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117678.txt

## Key facts
- Earnings Releases
  BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended September 30, 2023 results: net income Net loss for the three months ended September 30, 2023 was approximately $1.2 million, EPS Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively.
  - Period: the quarter ended September 30, 2023
  - Net income: Net loss for the three months ended September 30, 2023 was approximately $1.2 million
  - EPS: Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively
  - Result: reported results
  source text: BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/0001104659-23-117678-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.